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The amphiphilic peptide is becoming attractive as a potential drug carrier to improve the dissolvability of hydrophobic drugs in an
aqueous system; thus, facilitating drug uptake by target cells. Here, we report a novel designed amphiphilic peptide, Ac-RADAGAGA-
RADAGAGA-NH2, which was able to stabilize pyrene, a hydrophobic model drug we chose to study in aqueous solution. This designed
peptide formed a colloidal suspension by encapsulating pyrene inside the peptide–pyrene complex. Egg phosphatidylcholine (EPC) ves-
icles were used to mimic cell bilayer membranes. We found that pyrene was released from the peptide coating into the EPC vesicles by
mixing the colloidal suspension with EPC vesicles, which was followed by steady ﬂuorescence spectra as a function of time. A calibration
curve for the amount of pyrene released into the EPC vesicles at a given time was used to determine the ﬁnal concentration of pyrene
released into the lipid vesicles from the peptide–pyrene complex. The release rate of the peptide–pyrene complex was calculated to quan-
tify the transfer of pyrene into EPC vesicles.
 2009 National Natural Science Foundation of China and Chinese Academy of Sciences. Published by Elsevier Limited and Science in
China Press. All rights reserved.
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The self-assembly phenomenon of peptides bearing dif-
ferent sequences in an aqueous solution was discovered
over 10 years ago [1] and prompted numerous studies of
various nanostructures of such peptides [2–6]. Self-assem-
bly peptides have been used in many applications such as
3D cell cultures [7], tissue or organ injury repair systems
[8], biological surface engineering [9], and membrane pro-
tein stabilization [10]. In recent years, the study of self-
assembly peptides as hydrophobic drug carriers has
attracted great interest from scientists, and several types1002-0071/$ - see front matter  2009 National Natural Science Foundation o
and Science in China Press. All rights reserved.
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application of drug delivery systems [11–13]. To broaden
this ﬁeld, and to improve the compatibility between pep-
tides and hydrophobic drugs, other types of peptides
should be designed and investigated.
As native proteins, silk ﬁbroins have been proven to
be useful in drug delivery because of their good biocom-
patibility, hydrophobicity, and porous network structure
[14–16]. Poly-GA (where G is Glycine, and A is Alanine)
is a prevalent conservative motif in silk protein, particu-
larly in silk produced by the silk moth Bombyx mori.
This peptide occupies 40–50% of the total volume of
the silk ﬁber [17]. In silk ﬁbroin, the GA motif forms
a packed structure via hydrophobic interactions [18],
which facilitates the formation of networks in the silkf China and Chinese Academy of Sciences. Published by Elsevier Limited
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in silk protein, it is likely that the GA motif can play
an important role in the use of silk proteins in drug
delivery systems. However, the hydrophobicity of the
GA motif means low solubility of peptides such as
(GA)n and GnAm in water. Therefore, to design an
amphiphilic peptide containing the GA motif, it is
important to achieve this goal.
RADA16-I, Ac-RADARADARADARADA-NH2, is a
typical ionic self-complementary peptide with two distinct
surfaces—one hydrophilic, the other hydrophobic. It com-
prises 16 amino acids with alternating positively and nega-
tively charged amino acids, which are separated by a
hydrophobic amino acid [20]. The peptide, which has a
b-sheet secondary structure, can self-assemble into nanoﬁ-
ber scaﬀolds after being dissolved in an aqueous solution.
Furthermore, the peptide has been studied in many appli-
cations, including 3D cell culture [21] and tissue recovery
[22]. Because of its good solubility in water and ﬁbrous
structure, in this study, an amphiphilic peptide containing
the GA motif was designed based on the amino acid
sequence of RADA16-I. And its potential use as a drug
carrier was investigated.
We studied whether the novel peptide can stabilize
pyrene crystals (a hydrophobic drug model) in water,
because pyrene shows very poor dissolution in water,
which leads to diﬃculties in achieving delivery of drugs
to the target cell or location via body ﬂuid circulation.
We further studied whether the peptide could deliver
pyrene into the bilayer membranes of egg phosphatidyl-
choline (EPC) vesicles as carriers. Because of the
well-characterized ﬂuorescence of pyrene [23], steady-
state ﬂuorescence spectroscopy was used to obtain infor-
mation about the interaction of the peptide with pyrene.
We used atomic force microscopy (AFM) to investigate
the self-assembling nanostructure of the peptide, and
dynamic light scattering (DLS) to determine the size
distributions of EPC vesicles.2. Materials and methods
2.1. Materials
The peptide, Ac-RADAGAGARADAGAGA-NH2
(1399.41 g/mol), which was commercially synthesized and
puriﬁed (>95%) (Bootech BioScience & Technology Co.,
Ltd, Shanghai, China) was acetylated at N termini and
amidated at C termini. Egg phosphatidylcholine (EPC)
was purchased from Sinopharm Chemical Reagents Co.,
Ltd, Shenyang, China. Pyrene (99%) was obtained from
Sigma–Aldrich and was recrystallized from ethanol before
the experiment. The rest of the chemicals used in the exper-
iment were acquired from Chengdu Kelong Chemical
Reagents Co., Chengdu, China. All the aqueous solutions
were prepared using deionized water (ElixWater Puriﬁca-
tion System, Millipore, MA, USA).2.2. EPC vesicle preparation
EPC (0.8 g) was dissolved in chloroform. The organic
solvent was evaporated by a rotary evaporator at 25 C
to produce an EPC thin ﬁlm inside the round-bottom ﬂask.
Then, the EPC ﬁlm was exposed to high vacuum for at
least 2 h to remove any trace of chloroform and was resus-
pended in 300 ml of buﬀer solution (pH 7.4, containing
25 mM Tris–HCl acid and 0.2 mM EDTA). After being
bubbled with nitrogen, the mixture was sonicated for half
an hour at 0 C by a ultrasonic crasher set at about
200 W output. This was followed by centrifugation at
12,000 g for 1.5 h. The supernatant was ﬁltered by 0.44
and 0.22 lm membrane ﬁlters in turn. Liposome size was
measured by the Malvern Zetasizer Nano ZS analyzer.
2.3. Determination of the lipid concentration
One milliliter of the vesicle solution was pipetted into
each of three pre-weighed 20 ml vials. Tris–HCl acid and
EDTA buﬀer solution with the same volume were pipetted
into another three pre-weighed 20 ml vials. The three sets
of vesicle and buﬀer solutions were dried under a stream
of nitrogen to obtain a ﬁlm at the bottom of the vial.
The vials were then placed in a vacuum oven overnight
at 60 C to remove any trace of water. The mass of vesicles
was obtained by mass subtraction of two sets, and the aver-
age concentration of the vesicles in the buﬀer solution was
calculated. The deviation from the average concentration
was consistently less than 2.0%.
2.4. Preparation of colloidal suspensions of pyrene crystals
An appropriate amount of pyrene was dissolved in tetra-
hydrofuran, placed into a 10-ml vial, and dried under a
continuous stream of nitrogen. A freshly prepared peptide
solution was added to this vial and diluted with deionized
water to obtain the expected concentration of the solution.
The peptide–pyrene solution was prepared to a ﬁnal con-
centration of 0.53 mg/ml (3.79  104 M) for the peptide
and 0.9 mg/ml (4.45  103 M) for pyrene. The sample
solution was stirred for 5 days until an equilibrium was
reached. The solutions were deemed to have reached equi-
librium when their ﬂuorescence spectra did not change over
24 h.
2.5. Atom force microscope (AFM) observation
The peptide solution at a concentration of 1 mg/ml was
used. Five microliters of the sample was deposited onto a
freshly cleaved mica substrate. Each aliquot was left on
the mica for 1 min, then washed with deionized water,
and dried in air for about 20 min. The images were
obtained by scanning the mica surface in air by AFM
(SPA400, SII Nanotechnology, Inc.) operating in tapping
mode. Soft silicon cantilevers were chosen with a cantilever
length of 200 lm, a spring constant of 12 N/m, and a tip
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512  512-pixels resolution and produced topographic
images of the samples in which the brightness of the
features increases as a function of height. Typical scanning
parameters were as follows: vibrating frequency 124 kHz,
integral and proportional gains 0.1–0.4 and 0.01–0.03,
respectively, amplitude reference 0.1 to 0.25, and scan-
ning speed 0.8–1.2 Hz.
2.6. CD measurement
The circular dichroism (CD) spectra were obtained
using the sample solution at a concentration of
0.125 mg/ml. The CD spectrum between 190 and
260 nm was collected with the wavelength scan mode on
a Model 400 Circular Dichroism Spectrophotometer
(Aviv Biomedical, Inc.) at 20 C. A quartz cell of 0.1 cm
optical path length was chosen to hold the sample solu-
tion and placed in a chamber ﬂushed with N2. Every sam-
ple was scanned three times, and the spectra signal was
averaged and smoothed.
2.7. Steady-state ﬂuorescence measurements
Fluorescence spectra were recorded on a Hitachi F-7000
FL ﬂuorophotometer at room temperature. Solution sam-
ples were operated in a quartz ﬂuorescence cuvette of
1  1 cm cross-section, while solid samples were carried
out by using a solid accessory. Excitation and emission slits
were set to 5 and 2.5 nm, respectively. By setting the exci-
tation wavelength at 336 nm, the emission ﬂuorescence
spectra were scanned from 350 to 650 nm, with a scan
speed of 1200 nm/min. Excitation spectra were recorded
at the selected emission wavelengths (374 and 470 nm).
2.8. Calibration curve
Solutions of pyrene in EPC vesicles with pyrene concen-
trations ranging from 106 to 1.4  104 M and an EPC
concentration of 6.99  104 M were prepared by placing
an appropriate amount of pyrene dissolved in THF into
a 10 ml vial, and the solution was evaporated under a
stream of nitrogen to produce a ﬁlm of pyrene at the bot-
tom of the vial. The pyrene was then dissolved in 3 ml of
vesicle solution referred to as EPC–pyrene solutions. The
Im (ﬂuorescence intensity of the pyrene monomer) for the
EPC–pyrene samples was obtained by averaging the emis-
sion intensities of the pyrene monomer for the EPC–pyrene
solutions monitored at 374 nm for 120 s. In order to avoid
the inﬂuence of xenon lamp ﬂuctuations, the intensity of
the pyrene monomer standard (Is) is needed. A degassed
and sealed solution of pyrene dissolved in ethanol
([PY] = 3.85  105 M) was monitored at 374 nm for
120 s, and the measured intensity was averaged to yield Is
after each spectrum of the EPC–PY solutions. The cor-
rected value of the monomer intensity (Im/Is) for the
EPC–PY solutions was obtained by dividing Im by Is.2.9. Dynamic light scattering measurement (DLS)
The sample solution of 600 ll was used to perform the
measurement. The size distribution was determined by
using a laser diﬀraction particle sizer (Nano-ZS90,
Malvern). Each sample was ultrasonicated for 30 min using
an ultrasonic cleaner, and a low volume disposable sizing
cuvette was chosen to hold the sample solution. The inten-
sity for each sample was collected in three replicates and
yielded the size-fraction distribution plots. The tempera-
ture was kept at 25 C during measurement.
3. Results and discussion
3.1. Peptide nanoﬁbers and preparation of colloidal
suspensions of pyrene crystals
The peptide, Ac-RADAGAGARADAGAGA-NH2,
was commercially synthesized as a lyophilized powder.
Before each experiment, the peptide was mixed with deion-
ized water and stored at 4 C overnight. The ﬁbrous nano-
structure was observed using AFM and TEM, as shown in
Fig. 1. The peptide solution was clear with a pH of 3.5.
Based on the AMF images, the average length of nanoﬁ-
bers was 4 lm and the diameter was 90 nm. CD was used
to measure the secondary structure of the peptide. The
CD spectra of the amphiphilic peptide revealed a strong
negative peak at 194 nm and a weaker negative peak at
223 nm, which represented neither an a-helix nor b-sheet
structure (data not shown). This type of CD spectra has
been indicated to represent random-coil secondary struc-
tures in some reports [24].
Pyrene was chosen as the hydrophobic model drug in this
experiment because of its low solubility and wide applica-
tion as a molecular probe [25]. No static pyrene excimer
formed in the liposomes, as reported by Winnik [26], which
facilitated detection of the delivery of pyrene into the
phospholipid bilayer. An appropriate amount of peptide
solution was mixed with pyrene, while the same volume of
deionized water was added to the control sample. After stir-
ring for 2 h, the peptide–pyrene solution became turbid and
milky-white in color, which suggested a colloidal suspension
was obtained. However, because of the low solubility of pyr-
ene (about 6.0  107 M in a saturated aqueous solution
[23]), the control sample without peptide was still clear, with
pyrene crystals ﬂoating on the top or precipitating at the
bottom (Fig. 2). The sample solution was deemed to have
reached equilibrium after stirring for 5 days, as indicated
by a lack of change in ﬂuorescence spectra over 24 h. The
pH of the peptide–pyrene solution was about 3.48, which
was similar to that of the peptide in water. The formation
of a colloidal suspension suggested that the peptide had sta-
bilized the pyrene crystals in the aqueous solution
(4.45  103 M). Aggregation of a drug in an aqueous sys-
tem would prevent delivery of the drugs to the target cells
or location via body ﬂuid circulation; therefore, the
stabilization of the pyrene crystal means the likelihood for
Fig. 1. (a) Amino acid sequence of the self-assembly peptide and space-ﬁlling molecular model of a peptide approximately 6.2 nm long, 1 nm wide, and
0.5 nm thick. (b) and (c) show AFM images of the peptide nanoﬁber in water at diﬀerent scales, 6  6 lm (b), 2  2 lm (c). (d) TEM photo of the peptide
nanoﬁber in water at a concentration of 1 mg/ml.
Fig. 2. Pyrene ([Py] = 4.45  103 M) in deionized water (left), and the
peptide–pyrene solution ([Py] = 4.45  103 M, [Peptide] = 3.79 
104 M) (right) after stirring for about 2 h.
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tide–pyrene colloidal suspension, ﬁber-like peptides were
still found in the sample solution, which had a lower density
than that of the peptide in water at the same concentration
according to ﬁndings of the AFM observation. It seems
likely that the pyrene interacted with the hydrophobic
region of the peptide and formed a peptide–pyrene complex,
which decreased the formation of peptide nanoﬁbers. How-
ever, this ﬁnding needs to be further evaluated.3.2. Transfer of pyrene into the EPC vesicles
In order to target living cells, the hydrophobic drug
must cross the cell membrane. As lipids are the essentialcomponents of cell membranes, we used EPC vesicles as
a model membrane to investigate whether the pyrene mol-
ecules could be transferred into the lipid vesicles by peptide
carriers. The size distribution of the prepared EPC vesicles
was determined by dynamic light scattering. The dynamic
diameter of the vesicles ranged from 50 to 100 nm with
an average diameter of 75 nm, which were deﬁned as large
unilamellar vesicles (LUVs) as reported in Ref. [12]. The
ﬂuorescence spectra of the pyrene crystals and peptide–pyr-
ene solution at equilibrium were obtained using a ﬂuoro-
photometer. To investigate whether the transfer occurred,
a sample of the peptide–pyrene solution mixed with EPC
vesicles and a sample of pure pyrene in EPC vesicles were
used. The steady-state ﬂuorescence spectra are shown in
Fig. 3.
Mizusaki et al. [27] reported that pyrene monomers
exhibited ﬁve emission bands between 375 and 400 nm,
which were attributed to the emission of spatially isolated
pyrene groups, and this character could be used to identify
the pyrene monomer from the pyrene crystals. No emission
corresponding to pyrene monomers was found in the
steady-state ﬂuorescence spectra of pyrene crystals and
the peptide–pyrene solution, but a broad featureless band
was observed at around 470 nm, which is attributed to pyr-
ene excimer emission. Emission corresponding to the pyr-
ene monomer was observed in the spectra for pyrene in
the EPC vesicles and the peptide–pyrene solution mixed
with the vesicles, which were rather similar. According to
previous reports, the emission intensity ratio of the ﬁrst
(374 nm) to the third (385 nm) peak (I1/I3) is usually con-
sidered as a polarity measurement of the pyrene microenvi-
ronment [28]. This ratio equals 1.96 in polar solvents such
as water and decreases with increasing solvent apolarity. In
this experiment, the I1/I3 ratio of pyrene in EPC vesicles
and peptide–pyrene mixed with EPC were both 1.1, which
Fig. 3. Fluorescence emission spectra of solid pyrene crystals (a), peptide–pyrene solution ([Py] = 4.45  103 M, [Peptide] = 3.79  104 M) (b), pyrene
in EPC vesicles ([Py] = 5.00  105 M) (c), and peptide–pyrene solution mixed with EPC vesicles ([Py] = 4.45  105 M, [Peptide] = 3.79  106 M) (d).
The excitation wavelength was 336 nm. The excitation slit width and emission slit width for the solid pyrene crystals were 5 and 2.5 nm, respectively.
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vesicles. This provided further evidence that pyrene had
transferred into the cell membrane model from the peptide
coating. Moreover, the ratio of the emission intensity
between the excimer at about 470 nm and the monomer
emission maxima at about 374 nm (Ie/Im) can be used to
estimate the local viscosity in the host [29]. In this regard,
Ringsdorf et al. [30] used the ratio of pyrene excimer emis-
sion intensity and locally excited pyrene emission intensity
(Ie/Im) as a structure indicator for characterizing high local
pyrene concentration inside the liposome. In this experi-
ment, both spectra exhibited a very similar ratio Ie/Im of
0.55 for peptide–pyrene in EPC vesicles and 0.56 for pyrene
crystals in EPC vesicles, which indicated a similar excimer
emission intensity of the two systems in phospholipid
bilayers.
Because excimers were observed in the steady-state ﬂuo-
rescence spectra of both the pyrene crystals and the pyrene
in EPC vesicles, additional studies are needed to determine
whether the transfer of pyrene into EPC vesicles had
occurred. It has been reported that the pyrene excimer
has two forms: one is a dynamic excimer that is formed
via diﬀusional encounters between pyrene molecules, and
the other is a ground-state pyrenean static excimer that is
formed from the direct excitation of ground-state pyrene
dimers [31]. Thus, excitation spectra were investigated.
According to a previous study [32], the static excimer hasa red-shift excitation spectrum, and the dynamic excimer
has the same excitation spectrum as that of monomer emis-
sion (at the selected emission wavelength kem = 374 nm and
kem = 470 nm). The ﬂuorescence spectra obtained are
shown in Fig. 4.
As shown in Fig. 4(a) and (b), as compared with the
excitation spectrum monitored at monomer emission, the
excitation spectra of solid pyrene crystals and peptide–pyr-
ene at the excimer emission region were red-shifted by
about 35 nm from 333 to 368 nm. However, no shifts were
observed in the spectra of pyrene and peptide–pyrene solu-
tions in EPC vesicles, which indicated that the excimers in
pyrene crystals and the peptide–pyrene solution were static
excimers resulting from pyrene molecules that were pre-
associated in solid pyrene crystals. The excimers of pyrene
and peptide–pyrene solutions in EPC vesicles were dynamic
excimers which were formed via diﬀusion of dispersed pyr-
ene molecules [33].
To further investigate the transfer of pyrene from the
peptide coating into the EPC vesicles, we determined the
steady-state ﬂuorescence spectra of peptide–pyrene solu-
tions with EPC vesicles shortly after sample preparation.
Previously, Winnik et al. [34] used time-based ﬂuorescence
scans to monitor the increase in monomer emission as a
function of time, a method that can be used in our system.
Therefore, to observe the transfer of the pyrene in
the EPC–peptide–pyrene solution more precisely, we
Fig. 4. Normalized ﬂuorescence excitation spectra for solid pyrene crystals (a), peptide–pyrene solution ([Py] = 4.45  103 M, [Pep-
tide] = 3.79  104 M) (b), pyrene in EPC vesicles ([Py] = 5.00  105 M) (c), and the peptide–pyrene solution mixed with EPC vesicles
([Py] = 4.45  105 M, [Peptide] = 3.79  106 M) (d). The emission wavelength (kem) was 374 nm (—) and 470 nm (– – –).
Fig. 5. Fluorescence emission intensity of the pyrene monomer as a
function of time for release of pyrene from the peptide coating into EPC
vesicles. The excitation wavelength was 336 nm, and the emission
wavelength was 374 nm. The emission intensity (Im) was divided by that
of the standard (Is). Proﬁle (1): data obtained over 4 h at 2-s intervals
([Py] = 1.48  105 M, [Peptide] = 1.26  106 M, [EPC] = 6.99 
104 M). Proﬁle (2): data obtained over 4 h at 2-s intervals
([Py] = 7.40  105 M, [Peptide] = 6.30  106 M, [EPC] = 6.99 
104 M).
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function of time at an emission wavelength of 374 nm over
a period of 4 h at 2-s intervals. As determined from the
spectra, the I1/I3 ratio was 1.1, which indicated that the
pyrene monomer was always located inside the hydropho-
bic vesicle membrane. Two proﬁles are shown in Fig. 5.
Proﬁles 1 and 2 represent the release of pyrene from the
peptide solution into the EPC vesicles at ﬁnal pyrene con-
centrations of 1.48  105 and 7.40  105 M, respectively.
Proﬁle 1, at a low pyrene concentration, exhibits a contin-
uous increase in Im during the ﬁrst half hour, reaching a
plateau after 2 h. This indicates that, when the peptide–
pyrene solution was added to the EPC vesicles, the concen-
tration of pyrene monomers increased as the pyrene crys-
tals were transferred into the EPC vesicles, and the
likelihood for pyrene to absorb a photon increases in the
transition from the crystalline form to the monomer. Cor-
respondingly, Im reached a plateau when all of the pyrene
molecules were dissolved into the vesicles. Proﬁle 2, as
obtained at a higher concentration of pyrene, shows a
sharp increase in Im to a maximum after 24 min, which
was followed by a continuous decrease to a plateau that
was reached after about 1.5 h. Accordingly, if too much
pyrene was added to the liposome solution, the dissolution
of pyrene molecules in the EPC vesicles lead to greater pyr-
ene absorption. After the pyrene concentration in the lipo-somes reaches a critical level, the inner ﬁlter eﬀect takes
place [35], which leads to decreased ﬂuorescence of the pyr-
ene monomer until the crystals were fully dissolved and a
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other factors that could aﬀect these proﬁles, such as self-
quenching of the pyrene monomers and multiple scattering
with the EPC vesicles. However, the pyrene crystals were
often larger than the EPC vesicles, and self-quenching
was more likely to occur through the diﬀusional encounter
with another pyrene molecule dissolved in the liposome
bilayer. Consequently, these factors are expected to be sta-
tic with respect to the dissolution of the pyrene molecules
in the lipid bilayer. Multiple scattering might also be pres-
ent, but it would be expected to be greatly reduced because
we used the same liposome system for the calibration curve
and for the release experiments.Fig. 7. Proﬁles for the release of molecular pyrene from peptide-coated
pyrene crystals into a solution of EPC vesicles according to ﬂuorescence
results. The continuous dots represent the actual pyrene concentration,
and the dashed line was the data ﬁtted with a sigmoidal function.3.3. Generation of the calibration curve
A calibration curve was generated to obtain quantitative
information of the amount of pyrene to be transferred into
the liposome and was based on the data shown in Fig. 5. A
series of solutions of pyrene in EPC vesicles were prepared
with pyrene concentrations ranging from 1.0  106 to
1.3  105 M. The ﬂuorescence intensity of the pyrene
monomer divided by that of the standard to account for
lamp ﬂuctuations (Im/Is) is shown in Fig. 6 as a function
of the pyrene concentration. The calibration curves also
revealed the inner ﬁlter eﬀect as Im/Is passes through a
maximum, with little changes for pyrene concentrations
between 2.0  105 and 3.0  105 M. Therefore, a gap
was observed in the time-dependent concentration proﬁle
for pyrene located inside the vesicles, where no data points
were reported for pyrene concentrations in this range. Two
functions of Im/Is ﬁtted for diﬀerent pyrene concentration
ranges were obtained, and showed good ﬁt with a
sigmoidal function. At concentrations of pyrene up to
2.5  105 M, the monomer intensity was ﬁt with a
sigmoidal function, where Im/Is = 3.810  99.634/(1 +
e([Py]+20.245)/6.233), (R2 = 0.9920). Another sigmoidal func-
tion, Im/Is = 0.558 + 5.280/(1 + e
([Py]-40.081)/29.308), (R2 =Fig. 6. Calibration curve for diﬀerent pyrene concentrations in EPC
vesicles ([EPC] = 6.99  104 M). The ﬂuorescence intensity (Im) was
divided by that of the standard (Is) to account for lamp ﬂuctuations.0.9936) was used to ﬁt the monomer intensity for higher
pyrene concentrations.
By transforming the Im/Is-versus-time proﬁles with a
calibration curve of Im/Is-versus-concentration of pyrene
in EPCs, we developed a release curve of the concentra-
tion-versus-time proﬁles of pyrene from the peptide carrier
into EPC vesicles, as shown in Fig. 7. Over time, more pyr-
ene molecules were transferred from the peptide–pyrene
solution into the EPC vesicles, reaching a plateau as the
pyrene molecules were fully dissolved. The ﬁnal pyrene
concentrations of Proﬁles 1 and 2 were about 10.7 and
48.7 lM, respectively (Fig. 7). To describe the transfer of
pyrene from peptide into EPC vesicles, a release constant
is required. Although it is diﬃcult to establish a model
describing the uniqueness of the pyrene transfer, the pro-
ﬁles shown in Fig. 7 could be ﬁt with Eq. (1), where
[PY](t), [PY]eq, and [PY]0 represent the pyrene concentra-
tion inside the EPC vesicles at time t, at equilibrium (inﬁ-
nite time), and at time t = 0 s, respectively. The ktrans of
proﬁle 1 and proﬁle 2 of Fig. 7 were 3.32 ± 0.1/h and
3.51 ± 0.1/h, respectively.
½PYðtÞ ¼ ½PYeq  ð½PYeq  ½PY0Þ expðktrans  tÞ ð1Þ4. Conclusions
In the present study, we demonstrate that the novel
designed peptide, Ac-RADAGAGARADAGAGA-NH2,
can stabilize the crystals of a hydrophobic model com-
pound by mechanical stirring and forms a colloidal suspen-
sion. The steady-state ﬂuorescence spectra of the peptide–
pyrene solution and the peptide–pyrene solution in the
presence of EPCs showed that the pyrene crystals were
molecularly dissolved in the vesicular membrane. The
release behavior of pyrene into the EPC vesicles was inves-
tigated by steady-state ﬂuorescence spectra, and the pyrene
concentration in the EPC vesicles was determined as a
function of time. We also determined the concentration
of pyrene in EPC vesicles by comparing the monomer
signal with that of a calibration curve. The transfer rate
1536 Q. Zhou et al. / Progress in Natural Science 19 (2009) 1529–1536constants were also determined to quantify the transfer
behavior of pyrene into EPC vesicles. Our results suggest
that pyrene can be transferred into the lipid bilayers from
the novel designed amphiphilic peptide, and that the pep-
tide is a potential carrier for low molecular weight,
water-insoluble compounds.
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